# Cell and Gene Therapy for Personalised Medicine

**Funder:** Research Council of Norway
**Deadline:** 20 January 2027 (Pre-proposal deadline; call opens 4 November 2026; full proposal deadline 25 May 2027)
**Consortium:** Required — interdisciplinary, cross-sectoral research consortium under EP PerMed
**Application:** 2-stage: pre-proposal (20 January 2027) → full proposal (25 May 2027)
**TRL:** 3-6
**Frequency:** Annual
**Eligible countries:** NO
**Official call:** https://www.forskningsradet.no/en/call-for-proposals/International-joint-calls/cell-and-gene-therapy-personalised-medicine/
**Last updated:** 25 Oct 2026

## Eligibility & scope

Encourages interdisciplinary and cross-sectoral research collaborations on developing and validating innovative cell and gene therapy for personalised medicine, under the European Partnership for Personalised Medicine (EP PerMed).

## Summary

This Research Council of Norway call, run through the EP PerMed partnership, funds interdisciplinary and cross-sectorial research consortia developing and validating cell and gene therapy approaches for personalised medicine, at technology readiness levels 3-6. It is a one-off call open to Norwegian participants in cross-national consortia, structured as a two-stage application process.

## Who should apply

- Researchers in Norway working on cell or gene therapy development
- Consortia spanning multiple disciplines and sectors (academia, clinical, industry)
- Projects at TRL 3-6, bridging early validation toward application
- Teams able to coordinate across the EP PerMed partnership structure

## Key dates

- Call opens 4 November 2026; pre-proposal deadline 20 January 2027
- Full proposal deadline 25 May 2027
- Two-stage process: pre-proposal then full proposal

## Tips for applicants

- Form the cross-sectorial consortium early since EP PerMed calls require partners beyond a single academic discipline or sector.
- Position the project clearly within TRL 3-6, proposals too early-stage or too close to market may not fit the call's scope.
- Use the pre-proposal stage to establish the consortium's interdisciplinary rationale before investing in a full technical proposal.

## Frequently asked questions

### What is the deadline for the Cell and Gene Therapy for Personalised Medicine call?

The pre-proposal is due 20 January 2027, with the full proposal deadline on 25 May 2027.

### Is this call recurring?

No, it is listed as a one-off call.

### Do I need a consortium to apply?

Yes, an interdisciplinary and cross-sectorial research consortium is required under the EP PerMed partnership.

### What technology readiness level does this call target?

Projects should fall within TRL 3-6, covering early proof-of-concept through validation stages.

### Who is eligible to apply from Norway?

Norwegian researchers participating in the required cross-sectorial consortium, as this call is funded through the Research Council of Norway.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/research-council-of-norway-cell-and-gene-therapy-for-personalised-medicine-2027-01) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.

**See which EU calls match your profile.** [Preview your matches in 30 seconds, no signup](https://grantsby.eu/demo?ref=llm_grant_md&grant=research-council-of-norway-cell-and-gene-therapy-for-personalised-medicine-2027-01).